Program
Discovery
Lead Optimization
IND-Enabling
Phase 1
Phase 2
Phase 3
Partner
PRA023 - Anti-TL1A mAb
PR600 - Anti-TNF Super Family Member mAb
(1)
Europe Partnered
PR300 - Small Molecule GPCR Modulator
TPR15 - mAb
(2)

1) Prometheus retains all commercialization rights to PR600 outside of Europe, Australia and New Zealand
2) We are developing a companion diagnostic in tandem with Takeda's drug discovery and development efforts. Takeda has an option to collaborate on an additional program.

ProgramProgress
PRA023 IND-Enabling
PR600 Discovery
PR300 Discovery
TPR15 Discovery